A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma
J Rey,
Corresponding Author
J Rey
*Correspondence: J Rey. E-mail:
[email protected]Search for more papers by this author S Wickenhauser,
S Wickenhauser
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author V Ivanov,
V Ivanov
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author D Coso,
D Coso
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author JA Gastaut,
JA Gastaut
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author R Bouabdallah,
R Bouabdallah
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author
J Rey,
Corresponding Author
J Rey
*Correspondence: J Rey. E-mail:
[email protected]Search for more papers by this author S Wickenhauser,
S Wickenhauser
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author V Ivanov,
V Ivanov
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author D Coso,
D Coso
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author JA Gastaut,
JA Gastaut
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author R Bouabdallah,
R Bouabdallah
Department of Hematology, Cancer Center Institute J. Paoli – I. Calmettes, Marseille, France
Search for more papers by this author
First published: 20 January 2009
No abstract is available for this article.
References
- 1
Aurran-Schleinitz T,
Gravis G,
Vittot M
et al
. ‘One hour’ rituximab infusion is safe and improves patient care and outpatient unit management.
Blood
2005; 106: 4759
(Abstract).
- 2
Heinzerling LM,
Urbanek M,
Funk JO
et al
. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Cancer
2000; 89: 1835–1844.
- 3
Errante D,
Bernardi D,
Bianco A,
De Nardi S,
Salvagno L.
Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Ann Oncol
2006; 17: 1720–1721.
- 4
Perez-Soler R,
Saltz L.
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
J Clin Oncol
2005; 23: 5235–5246.
- 5
Gerecitano J,
Goy A,
Wright J
et al
. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Br J Haematol
2006; 134: 391–398.
